BinD19 / Shenzhen BinDeBio - LARVOL DELTA

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects (clinicaltrials.gov) - P1/2; N=20; Active, not recruiting; Sponsor: Shenzhen BinDeBio Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Jun 2020 ➔ May 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukaemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects (clinicaltrials.gov) - P1/2; N=24; Active, not recruiting; Sponsor: Shenzhen BinDeBio Ltd.; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Jun 2020 ➔ May 2021

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukaemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects (clinicaltrials.gov) - P1/2; N=24; Active, not recruiting; Sponsor: Shenzhen BinDeBio Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed